Venous Thromboembolism: Mechanisms, Treatment, and Public Awareness

The Epidemiology of Venous Thromboembolism in the Community

John A. Heit

Venous thromboembolism is a major health problem. The average annual incidence of venous thromboembolism among Whites is 108 per 100,000 person-years,1,2 with about 250,000 incident cases occurring annually among US Whites. The incidence appears to be similar or higher among Blacks and lower among Asian- and Native-Americans.3,4 Adjusting for the different age and sex distribution of African-Americans, the venous thromboembolism incidence is about 78 per 100,000, suggesting that about 27,000 incident venous thromboembolism cases occur annually among US Blacks. Recent modeling suggests that more than 900,000 incident or recurrent, fatal and nonfatal VTE events occur in the US annually.5 The incidence of venous thromboembolism has not changed significantly over the last 25 years.2

Venous thromboembolism is predominantly a disease of older age.1,2,6 Incidence rates increase exponentially with age for both men and women and for both deep vein thrombosis and pulmonary embolism.1,2,6 The overall age-adjusted incidence rate is higher for men (114 per 100,000) than women (105 per 100,000; male:female sex ratio is 1.2:1).1,2 Incidence rates are somewhat higher in women during the childbearing years, whereas incidence rates after age 45 years are generally higher in men. Pulmonary embolism accounts for an increasing proportion of venous thromboembolism with increasing age for both genders.1

Survival After Deep Vein Thrombosis and Pulmonary Embolism

Observed survival after venous thromboembolism is significantly worse than expected survival for age and gender, and survival after pulmonary embolism is much worse than after deep vein thrombosis alone.7,8 The risk of early death among patients with symptomatic pulmonary embolism is 18-fold higher compared to patients with deep vein thrombosis alone.7 Pulmonary embolism is an independent predictor of reduced survival for up to 3 months after onset. For almost one-quarter of pulmonary embolism patients, the initial clinical presentation is sudden death. The annual number of pulmonary embolism-related deaths in the US may exceed myocardial infarction-related deaths and also stroke-related deaths.5

Venous Thromboembolism Recurrence

Venous thromboembolism is a chronic disease with episodic recurrence; about 30% of patients develop recurrence within the next 10 years.9,10 The hazard of recurrence varies with the time since the incident event and is highest within the first 6 to 12 months. Although anticoagulation is effective in preventing recurrence, the duration of anticoagulation does not affect the risk of recurrence once primary therapy for the incident event is stopped.10,11 Independent predictors of recurrence include male gender,12 increasing patient age and body mass index, neurological disease with leg paresis, and active cancer.6,9,10,13 Additional predictors include “idiopathic” venous thromboembolism,13 a lupus anticoagulant or antiphospholipid antibody,14,15 antithrombin, protein C or protein S deficiency,16 and possibly persistently increased plasma fibrin D-dimer17 and residual venous thrombosis.18

Complications of Venous Thromboembolism

The major complications of venous thromboembolism are venous stasis syndrome (ie, postthrombotic syndrome) and venous ulcer, and chronic thromboembolic pulmonary hypertension. The overall incidence of venous stasis syndrome and venous ulcer in the US is 76.1 and 18.0 per 100,000 person-years, respectively.19 Venous thromboembolism accounts for about 12% of all venous stasis syndrome cases occurring in the community.19 Venous thromboembolism patients have a 17-fold increased risk of venous stasis syndrome.19 The 20-year cumulative incidence of venous stasis syndrome after venous thromboembolism and after proximal deep vein thrombosis are about 25% and 40%, respectively.10,20,21 The 20-year cumulative incidence of venous ulcer is 3.7%.21

The incidence of chronic thromboembolic pulmonary hypertension is 6.5 per million person-years.22 Applying these incidence rates to the 2000 US White population, approximately 1400 new chronic thromboembolic pulmonary hypertension cases occur in the US annually.

Risk Factors for Venous Thromboembolism

To reduce venous thromboembolism incidence, persons at risk for venous thromboembolism must first be identified. Independent risk factors for venous thromboembolism include increasing patient age, surgery, trauma, hospital or
nursing home confinement, active cancer with or without concurrent chemotherapy, central vein catheterization or transvenous pacemaker, prior superficial vein thrombosis, varicose veins, and neurological disease with leg paresis; patients with chronic liver disease have a reduced risk.\textsuperscript{23,24} The incidence of VTE increases significantly with age for both idiopathic and secondary VTE, suggesting that the risk associated with advancing age may be attributable to the biology of aging rather than simply an increased exposure to VTE risk factors with advancing age.\textsuperscript{25} Compared to residents in the community, hospitalized residents have more than a 100-fold increased incidence of acute venous thromboembolism.\textsuperscript{26} Hospitalization and nursing home residence together account for almost 60\% of incident venous thromboembolism events occurring in the community.\textsuperscript{27} Thus, hospital confinement provides an important opportunity to significantly reduce venous thromboembolism incidence. Of note, hospitalization for medical illness and hospitalization for surgery account for almost equal proportions of venous thromboembolism (22\% and 24\%, respectively), emphasizing the need to provide prophylaxis to both of these risk groups. Nursing home residence independently accounts for more than one-tenth of all venous thromboembolism disease in the community.\textsuperscript{27}

Active cancer accounts for almost 20\% of incident venous thromboembolism events occurring in the community.\textsuperscript{27} The risk appears to be higher for patients with pancreatic cancer, lymphoma, malignant brain tumors, cancer of the liver, leukemia, and colorectal and other digestive cancers.\textsuperscript{28} Cancer patients receiving immunosuppressive or cytotoxic chemotherapy are at even higher risk for venous thromboembolism.\textsuperscript{23}

The risk among surgery patients can be further stratified based on patient age, type of surgery, and the presence of active cancer.\textsuperscript{29,30} The incidence of postoperative venous thromboembolism is increased with advancing patient age.\textsuperscript{30,31} High-risk surgical procedures include neurosurgery, major orthopedic surgery of the leg, thoracic, abdominal or pelvic surgery for malignancy, renal transplantation, and cardiovascular surgery.\textsuperscript{30} After controlling for the type of surgery and active cancer, additional independent risk factors for venous thromboembolism within 3 months after major surgery include increasing body mass index, intensive care unit admission for 6 days or longer, a central venous catheter, prolonged immobility, varicose veins, and infection.\textsuperscript{31,32}

Among patients hospitalized for acute medical illness, active cancer is a major venous thromboembolism risk factor. After controlling for cancer, additional independent risk factors for venous thromboembolism within 3 months after hospitalization for acute medical illness include increasing age and BMI, neurological disease with leg paresis, fracture, chronic renal disease, central venous catheter, prior superficial vein thrombosis, and prolonged immobility.\textsuperscript{33}

Medical conditions associated with VTE include heparin-induced thrombocytopenia, myeloproliferative disorders especially polycythemia rubra vera and essential thrombocythemia, intravascular coagulation and fibrinolysis/disseminated intravascular coagulation, nephrotic syndrome, paroxysmal nocturnal hemoglobinuria, thromboangiitis obliterans (Buerger disease), thrombotic thrombocytopenic purpura, Behcet syndrome, systemic lupus erythematosus, inflammatory bowel disease, homocystinuria, and possibly hyperhomocysteinemia.\textsuperscript{34,35} The risk associated with congestive heart failure, independent of hospitalization, is low.\textsuperscript{23,24} Long haul (>6 h) air travel is associated with a slightly increased risk for venous thromboembolism that is preventable with graduated compression stockings.\textsuperscript{36}

Among women, additional risk factors for venous thromboembolism include oral contraceptive use and hormone therapy,\textsuperscript{37} pregnancy and the postpartum period,\textsuperscript{24,38} and therapy with the selective estrogen receptor modulator, raloxifene. First and third generation oral contraceptives convey higher risk than second generation oral contraceptives.\textsuperscript{37} Hormone therapy is associated with a 2- to 4-fold increased risk of venous thromboembolism,\textsuperscript{39} but the risk may vary by type of estrogen.\textsuperscript{40} The overall incidence of pregnancy-associated venous thromboembolism is about 200 per 100 000 woman-years; compared to nonpregnant women of childbearing age, the relative risk is increased about 4-fold.\textsuperscript{38} The risk during the postpartum period is about 5-fold higher than the risk during pregnancy.\textsuperscript{38}

The Genetic Epidemiology of Venous Thromboembolism

Recent family-based studies indicate that venous thromboembolism is highly heritable and follows a complex mode of inheritance involving environmental interaction.\textsuperscript{41,42} Inherited reductions in plasma natural anticoagulants (eg, antithrombin, protein C, or protein S) have long been recognized as uncommon but potent risk factors for venous thromboembolism.\textsuperscript{33} More recent discoveries of impaired downregulation of the procoagulant system (eg, activated protein C [APC] resistance, Factor V Leiden), increased plasma concentrations of procoagulant factors (eg, factors I [fibrinogen], II [prothrombin], VIII, IX, and XI) and increased basal procoagulant activity, impaired fibrinolysis, and increased basal innate immunity activity and reactivity have added new paradigms to the list of inherited or acquired disorders predisposing to thrombosis (thrombophilia). Inherited thrombophilias interact with such clinical risk factors (eg, environmental risk factors) as oral contraceptives, pregnancy, hormone therapy, and surgery to increase the risk of incident venous thromboembolism. Similarly, genetic interaction increases the risk of incident and recurrent venous thromboembolism. These findings support the hypothesis that an acquired or inherited thrombophilia may predict the subset of persons exposed to common risk factors who actually develop symptomatic venous thromboembolism.

Sources of Funding

This work was funded, in part, by grants from the National Institutes of Health (HL66216, HL83141, HL83797, AR30582) and the Centers for Disease Control and Prevention (DD00235), US Public Health Service; and by Mayo Foundation.

Disclosures

None.
References


The Epidemiology of Venous Thromboembolism in the Community
John A. Heit

doi: 10.1161/ATVBAHA.108.162545
Arteriosclerosis, Thrombosis, and Vascular Biology is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2008 American Heart Association, Inc. All rights reserved.
Print ISSN: 1079-5642. Online ISSN: 1524-4636

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://atvb.ahajournals.org/content/28/3/370

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Arteriosclerosis, Thrombosis, and Vascular Biology can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Arteriosclerosis, Thrombosis, and Vascular Biology is online at:
http://atvb.ahajournals.org//subscriptions/